Thus, this in vivo experiment showed that TRIB1 overexpression enhanced tumor growth, which involved TRIB1-MEK1 interaction, suggesting that TRIB1 may serve as a druggable target in GBM. Here, MAP2K1 is linked to glioblastoma.